Online citations, reference lists, and bibliographies.
← Back to Search

Management Of Recurrent Pleural Mesothelioma: Successful Rechallenge With Nintedanib In Combination With Chemotherapy

F. Grosso, A. Roveta, G. Gallizzi, M. Belletti
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare neoplasm, generally caused by asbestos exposure. This case details how a patient treated with nintedanib during the LUME‐Meso study was rechallenged with nintedanib. The findings highlight the benefit of nintedanib rechallenge and the potential use of continuous anti‐angiogenic therapy in MPM treatment.
This paper references
10.1016/j.pop.2012.03.010
Strategies to improve the management of depression in primary care.
J. Unützer (2012)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.2147/LCTT.S83338
Modern management of malignant pleural mesothelioma
S. Patel (2016)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
Second- or thirdline nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT- 1501 MAPS2 randomized phase II trial
A Scherpereel (2017)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1186/1756-0500-5-482
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1200/JCO.2017.72.9012
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
F. Grosso (2017)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesotheli
J Stebbing (2015)
10.1097/JTO.0b013e318248242c
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report
A. Dudek (2012)
10.1200/JCO.2010.28.15_SUPPL.7020
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
G. Zalcman (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar